<DOC>
	<DOCNO>NCT01467349</DOCNO>
	<brief_summary>This retrospective analysis efficacy , safety tolerability raltegravir part optimize therapy clinical setting . Follow-up calculate treatment initiation ( without raltegravir ) date discontinuation consider regimen date last visit date lose follow-up , whichever come first . The Aim study evaluate efficacy safety raltegravir-containing regimen urban clinic setting .</brief_summary>
	<brief_title>Efficacy Raltegravir Large Urban HIV Clinical Population Milan</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Subjects receive raltegravir previously expose NRTIs , NNRTIs , PIs , regardless stage HIV disease start treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Raltegravir</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>raltegravir-containing regimen</keyword>
	<keyword>HIV urban clinic set</keyword>
</DOC>